Kiadis and Gulf Coast Regional Blood Center announce collaboration to provide universal donor material for K-NK cell therapy ...
28 Setembro 2020 - 2:00AM
Collaboration marks first contractual partnership
with supplier of universal donor material
Amsterdam, The Netherlands, September
28, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext
Amsterdam and Brussels: KDS), a clinical-stage
biopharmaceutical company developing innovative NK-cell-based
medicines for the treatment of life-threatening diseases and Gulf
Coast Regional Blood Center (GCRBC), a primary supplier of blood
components to more than 170 hospitals and health care facilities,
today announce a collaboration under which GCRBC will supply
universal donor starting material for the manufacture of Kiadis'
off-the-shelf K-NK Natural Killer (NK) cell therapies in the United
States.
Kiadis' proprietary off-the-shelf K-NK cell
platform is based on NK cells from unique universal donors. This
collaboration will provide Kiadis with an ongoing supply of
starting material needed for clinical supply and research and
development. The Company is developing multiple K-NK programs
utilizing universal donor starting material.
Arthur Lahr, chief executive officer of Kiadis,
commented, “Our collaboration with Gulf Coast Regional Blood Center
gives us access to their broad donor network to identify universal
donors using our proprietary algorithm and selection analytics. We
then take the donor immune cells as source material to produce
off-the-shelf K-NK cells. This collaboration further helps us
ensure a continued supply of universal donor material for our K-NK
cell therapy programs."
Hope Guidry-Groves, Cellular Life Solutions
Director at Gulf Coast Regional Blood Center, stated, "Our mission
is to partner with the community to help save and sustain lives by
providing a safe supply of blood, biotherapies and related
services. With our history of excellence and proven
expertise, we can help drive more treatment options to patients
through advanced blood therapies. By helping researchers locate
willing and eligible participants for these specialized
collections, we are doing our part in bringing new hope to
patients."
Dutch Translation/Nederlandse
vertaling
Kiadis Pharma nv ('Kiadis') is
een Nederlands beursgenoteerd biotechbedrijf dat nieuwe
geneesmiddelen ontwikkelt tegen ernstige ziekten. Het maakt daarbij
gebruik van Natural Killer-cellen (NK-cellen), grote witte
bloedlichamen die de eerste verdedigingslinie in het menselijk
afweersysteem vormen tegen kankercellen en infecties. Kiadis heeft
met de Amerikaanse bloedbank Gulf Coast Regional Blood Center
(GCRBC) in Housten, een overeenkomst gesloten voor de levering van
universeel donormateriaal voor productie van K-NK Natural
Killercel-therapie-producten. GCRBC is een belangrijke leverancier
van bloedproducten aan meer dan 170 ziekenhuizen en
zorginstellingen in de regio. Met de samenwerking is Kiadis
gegarandeerd voorzien van basismateriaal..
Arthur Lahr, CEO van Kiadis, zegt over
de samenwerking: “De alliantie met Gulf Coast Regional
Blood Center met haar brede donornetwerk geeft ons de mogelijkheid
universele donoren te identificeren met onze eigen algoritmen en
selectieprocessen. Deze samenwerking zorgt voor een continue
aanvoer van basismateriaal voor de productie van K-NK-cellen voor
al onze celtherapieën."
Hope Guidry-Groves, Cellular Life
Solutions Director bij GCRBC zegt: "Wij willen bijdragen
aan de volksgezondheid door veilige bloedvoorziening en meer
behandelopties voor patiënten via geavanceerde bloedtherapieën.
Door Kiadis bij te staan dragen wij bij aan een nieuw perspectief
voor patiënten.”
Dit persbericht vormt een samenvatting
van het gepubliceerde Engelstalige persbericht. Bij eventuele
verschillen is de tekst van het Engelstalige persbericht altijd
leidend.
Contacts
Kiadis: Maryann
Cimino, Sr. Manager, Corporate Affairs Tel: +1 617 710-7305
m.cimino@kiadis.com Gulf Coast Regional Blood
Center: Kellye Moran, Media Coordinator Tel: +1 713
791-6209kmoran@giveblood.org |
LifeSpring Life Sciences
Communication:Leon Melens (Amsterdam)Tel: +31 538 16
427lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
About Kiadis
Founded in 1997, Kiadis is building a fully
integrated biopharmaceutical company committed to developing
innovative cell-based medicines for patients with life-threatening
diseases. With headquarters in Amsterdam, The Netherlands, and
offices and activities across the United States, Kiadis is
reimagining medicine by leveraging the natural strengths of
humanity and our collective immune system to source the best cells
for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
About Gulf Coast Regional Blood
Center
Gulf Coast Regional Blood Center, based in
Houston, Texas, is the primary supplier of blood components to more
than 170 hospitals and health care facilities in a 26-county Texas
Gulf Coast region. Gulf Coast Regional Blood Center is a non-profit
501 (c) (3) organization and is accredited, licensed and inspected
by the Food and Drug Administration (FDA), AABB as well as local
and state authorities. The Blood Center is a proud member of AABB,
Blood Centers of America, South Central Association of Blood Banks,
the Texas Medical Center and America's Blood Centers. Gulf Coast
Regional Blood Center is an independent, non-profit blood center
that is not affiliated with the American Red Cross.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis' or, as appropriate, Kiadis'
officers' current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.